Global Oral Colchicine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oral Colchicine Market Research Report 2024
Oral colchicine refers to the formulation of the medication colchicine that is intended for oral administration. Colchicine is a medication derived from the plant Colchicum autumnale, also known as the autumn crocus or meadow saffron. It has been used for centuries as a medicinal agent, particularly in the treatment of gout and other inflammatory conditions.
Oral colchicine is available in the form of tablets or capsules, and it is typically taken by mouth. The medication is rapidly absorbed in the gastrointestinal tract and enters the bloodstream to exert its effects. Colchicine works by inhibiting inflammation and reducing the buildup of uric acid crystals in the joints, which is the underlying cause of gout.
According to Mr Accuracy reports’s new survey, global Oral Colchicine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Colchicine market research.
Key manufacturers engaged in the Oral Colchicine industry include Hikma Pharmaceuticals, Takeda Pharmaceuticals, Viatris, ROMEG Therapeutics, Major Pharmaceuticals, Zydus Pharmaceuticals, Par Pharmaceuticals and KPC Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Oral Colchicine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Oral Colchicine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Colchicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Hikma Pharmaceuticals
Takeda Pharmaceuticals
Viatris
ROMEG Therapeutics
Major Pharmaceuticals
Zydus Pharmaceuticals
Par Pharmaceuticals
KPC Pharmaceuticals
Segment by Type
Oral Tablet
Oral Capsule
Oral Solution
Gout
Familial Mediterranean Fever (FMF)
Pericarditis
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Colchicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Oral colchicine is available in the form of tablets or capsules, and it is typically taken by mouth. The medication is rapidly absorbed in the gastrointestinal tract and enters the bloodstream to exert its effects. Colchicine works by inhibiting inflammation and reducing the buildup of uric acid crystals in the joints, which is the underlying cause of gout.
According to Mr Accuracy reports’s new survey, global Oral Colchicine market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Colchicine market research.
Key manufacturers engaged in the Oral Colchicine industry include Hikma Pharmaceuticals, Takeda Pharmaceuticals, Viatris, ROMEG Therapeutics, Major Pharmaceuticals, Zydus Pharmaceuticals, Par Pharmaceuticals and KPC Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Oral Colchicine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Oral Colchicine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oral Colchicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Hikma Pharmaceuticals
Takeda Pharmaceuticals
Viatris
ROMEG Therapeutics
Major Pharmaceuticals
Zydus Pharmaceuticals
Par Pharmaceuticals
KPC Pharmaceuticals
Segment by Type
Oral Tablet
Oral Capsule
Oral Solution
Segment by Application
Gout
Familial Mediterranean Fever (FMF)
Pericarditis
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Colchicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source